Is primary prevention of Clostridium difficile infection possible with specific probiotics?

International Journal of Infectious Diseases

Volumn 16, Issue 11, 2012, Pages

  Johnson, Stuart ^a   Maziade, Pierre Jean ^b   McFarland, Lynne V ^c   Trick, William ^d   Donskey, Curtis ^e   Currie, Brian ^f   Low, Donald E ^g   Goldstein, Ellie J C ^h  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Centre Hospitalier Pierre Le Gardeur Terrebonne   (Canada)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d Vet Aff Chicago Hlth Care Syst   (United States)

^e LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibiotic associated diarrhea; CDI; Clostridium difficile; Prevention; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; PLACEBO; PROBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BIFIDOBACTERIUM BIFIDUM; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; NONHUMAN; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; PRIMARY PREVENTION; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84868195398     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.06.005     Document Type: Article

References (51)

1. Johnson S., Samore M.H., Farrow K.A., Killgore G.E., Tenover F.C., Lyras D., et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999, 341:1645-1651.
2. Gorbach S.L. Probiotics in gastrointestinal health. Am J Gastroenterol 2000, 95(1 Suppl):S2-S4.
3. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97:1769-1775.
4. Shim J.K., Johnson S., Samore M.H., Bliss D.Z., Gerding D.N. Primary symptomless colonization by Clostridium difficile and decreased risk of subsequent diarrhea. Lancet 1998, 351:633-636.
5. McFarland L.V. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009, 15:274-280.
6. Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 2009, 15:281-284.
7. Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999, 67:302-307.
8. Beausoleil M., Fortier N., Guénette S., L'Ecuyer A., Savoie M., Franco M., et al. Effect of a fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 2007, 21:732-736.
9. Psaradellis E., Sampalis J., Rampakakis E. Efficacy of BioK+ CL1285 in the reduction of antibiotic-associated diarrhea-a placebo controlled double-blind randomized, multi-center study. Arch Med Sci 2010, 6:56-64.
10. Gao X.W., Mubasher M., Fang C.Y., Reifer C., Miller L.E. Dose-response efficacy of probiotic prophylaxis for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea in adult patients. Am J Gastroenterol 2010, 105:1636-1641.
11. Millette M., Luquet F.-M., Ruiz M.T., Lacroix M. Characterization of probiotic properties of Lactobacillus strains. Dairy Sci Technol 2008, 88:695-705.
12. Goldstein EJ, Citron DM. Bacterial counts from six OTC probiotics: are you getting what you paid for? Presented at the 11th Biennial Congress of the Anaerobe Society of the Americas, San Francisco, California, USA, June 29-July 1, 2012.
13. Elmer G.W., McFarland L.V., Surawicz C.M., Danko L., Greenberg R.N. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999, 13:1663-1668.
14. Wilson K.H., Silva J., Fekety F.R. Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis. Infect Immun 1981, 34:626-628.
15. Aas J., Gessert C.E., Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003, 36:580-585.
16. Sambol S.P., Merrigan M.M., Tang J.K., Johnson S., Gerding D.N. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 2002, 186:1781-1789.
17. Elmer G.W., McFarland L.V. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother 1987, 31:129-131.
18. Castex F., Corthier G., Jouvert S., Elmer G.W., Lucas F., Bastide M. Prevention of C. difficile induced PMC by S. boulardii. J Gen Microbiol 1990, 136:1085-1089.
19. Naaber P., Mikelsaar R.H., Salminen S., Mikelsaar M. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol 1998, 47:591-598.
20. Kaur S., Vaishnavi C., Ray P., Kochhar R., Prasad K.K. Effect of biotherapeutics on cyclosporin-induced Clostridium difficile infection in mice. J Gastroenterol Hepatol 2010, 25:832-838.
21. Venugopalan V., Shriner K.A., Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis 2010, 16:1661-1665.
22. Salminen M.K., Tynkkynen S., Rautelin H., Saxelin M., Vaara M., Ruutu P., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002, 35:1155-1160.
23. Sullivan A., Nord C.E. Probiotic lactobacilli and bacteraemia in Stockholm. Scand J Infect Dis 2006, 38:327-331.
24. Boyle R.J., Robins-Browne R.M., Tang M.L. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 2006, 83:1256-1264.
25. Snydman D.R. The safety of probiotics. Clin Infect Dis 2008, 46(Suppl 2):S104-S111.
26. Ledoux D., Labombardi V.J., Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int J STD AIDS 2006, 17:280-282.
27. Land M.H., Rouster-Stevens K., Woods C.R., Cannon M.L., Cnota J., Shetty A.K. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005, 115:178-181.
28. Salminen M.K., Rautelin H., Tynkkynen S., Poussa T., Saxelin M., Valtonen V., et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004, 38:62-69.
29. Mackay A.D., Taylor M.B., Kibbler C.C., Hamilton-Miller J.M. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999, 5:290-292.
30. Simkins J, Kaltsas A, Currie B. Investigation of probiotic use among inpatients at an academic medical center. Presented at the 5th Decennial International Conference on Health Care-Associated Infections, Atlanta, Georgia, USA, March 18-22, 2010.
31. Maziade PJ, Gagne D, Andriessen A, Murray G, Jacob C, Pereira P, et al. Prospective cohort study on the efficacy of a probiotic in the prevention of Clostridium difficile associated diarrhea in hospital patients. Presented at the 6th International Symposium on Probiotics, Montreal, Canada, October 28-29, 2010.
32. Shaw R.L., Booth A., Sutton A.J., Miller T., Smith J.A., Young B., et al. Finding qualitative research: an evaluation of search strategies. BMC Med Res Methodol 2004, 4:5-9.
33. Surawicz C.M., Elmer G.W., Speelman P., McFarland L.V., Chinn J., van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989, 96:981-988.
34. McFarland L.V., Surawicz C.M., Greenberg R.N., Elmer G.W., Moyer K.A., Melcher S.A., et al. Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995, 90:439-448.
35. Lewis S.J., Potts L.F., Barry R.E. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998, 36:171-174.
36. Can M., Beşirbellioglu B.A., Avci I.Y., Beker C.M., Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit 2006, 12:PI19-PI22.
37. Harris R.J., Bradburn M.J., Deeks J.J., Harbord R.M., Altman D.G., Sterne J.A. Metan: fixed- and random-effects meta-analysis. Stata J 2008, 8:3-28.
38. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
39. Plummer S., Weaver M.A., Harris J.C., Dee P., Hunter J. Clostridium difficile pilot study: effect of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004, 7:59-62.
40. Thomas R.T., Litin S.C., Osmon D.R., Corr A.P., Weaver A.L., Lohse C.M. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomised, placebo-controlled trial. Mayo Clin Proc 2001, 76:883-889.
41. Hickson M., D'Souza A.L., Muthu N., Rogers T.R., Want S., Rajkumar C., et al. Use of probiotic Lactobacillus to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled study. BMJ 2007, 335:80-83.
42. Stein G.Y., Nanim R., Karniel E., Moskowitz I., Zeidman A. Probiotics as prophylactic agents against antibiotic-associated diarrhea in hospitalized patients. Harefuah 2007, 146:520-522.
43. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
44. Klarin B., Wullt M., Palmquist I., Molin G., Larsson A., Jeppsson B. Lactobacillus plantarum 299v reduces colonization of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand 2008, 52:1096-1102.
45. Graul T., Cain A.M., Karpa K.D. Lactobacillus and bifidobacteria combinations: a strategy to reduce hospital-acquired Clostridium difficile diarrhea incidence and mortality. Med Hypotheses 2009, 73:194-198.
46. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
47. Wilcox M.H., Sandoe J.A. Probiotics and diarrhoea: results are not widely applicable. BMJ 2007, 335:171.
48. Billyard T. Probiotics and diarrhoea: no high risk antibiotics?. BMJ 2007, 335:171.
49. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
50. Dethlefsen L., Huse S., Sogin M.L., Relman D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008, 6:e280.
51. Chang J.Y., Antonopoulos D.A., Kalra A., Tonelli A., Khalife W.T., Schmidt T.M., et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008, 197:435-438.